Kåre Schultz, outgoing Teva Pharmaceuticals CEO

Eu­ro­pean Com­mis­sion ac­cus­es Te­va of an­ti­com­pet­i­tive scheme as Co­pax­one sales sink

As gener­ic ri­vals cut in­to sales of Te­va Phar­ma­ceu­ti­cals’ block­buster mul­ti­ple scle­ro­sis drug Co­pax­one in North Amer­i­ca, the com­pa­ny has been ac­cused of breach­ing an­titrust …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.